Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 11% today. This is why it happened.

Vir Biotechnology Stock (VIR): Why The Price Jumped Today

GlaxoSmithKline

GlaxoSmithKline plc (NYSE: GSK) said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc (NASDAQ: VIR) is effective against all mutations of the new Omicron coronavirus variant, citing new data from preclinical studies. The data shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein.

Preclinical Data Shows GSK-Vir COVID-19 Drug Works Against All Omicron Mutations

A second batch of preclinical data shows sotrovimab is effective against all 37 mutations identified to date in the spike protein of Omicron.

Glaxo and Vir Antibody Drug Works on Omicron Mutations, New Data Show

--Company to Host Conference Call on Tuesday, December 7, 2021, at 8:30 am ET-- --Company to Host Conference Call on Tuesday, December 7, 2021, at 8:30 am ET--

Vir Biotechnology to Host a Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant

– New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus updated to bioRxiv

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant

Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.

Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 20% pre-market today. This is why it happened.

Vir Biotechnology (VIR) Stock: Why The Price Surged Today

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced an update to bioRxiv, a preprint server, with preclinical data for sotrovimab, COVID-19 targeting monoclonal antibody. The data demonstrated that sotrovimab retains activity against key mutations of the new Omicron SARS-CoV-2 variant, including those found in the binding site of sotrovimab.

Vir Biotech - GSK's COVID-19 Antibody Shows Preclinical Activity Against Omicron Variant

GlaxoSmithKline says early tests show that its antibody treatment was effective against the new strain, which was first identified in southern Africa.

Glaxo and Vir Say Early Tests Show Antibody Drug Works Against Omicron

– Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron –

Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

Johnson & Johnson

Merck

Novavax

Pfizer

Could biotech stocks be top buys as the world battles a new Covid-19 variant?

5 Biotech Stocks For Your December 2021 Watchlist

The shares of Vir Biotechnology Inc (NASDAQ: VIR) have received a price target of $200 from H.C. Wainwright.

Vir Biotechnology (VIR) Stock: $200 Price Target From H.C. Wainwright

H.C. Wainwright has raised the Vir Biotechnology Inc (NASDAQ:VIR) price target to $200 from $135, suggesting an upside of 330%. Analyst Patrick Trucchio reiterates a Buy rating on the stock.

Why Did HC Wainwright Beef Up Vir Biotech's Target Price?

An analyst upped his price target for the biotech stock.

Why Vir Biotechnology Stock Is Soaring Today

Adagio Therapeutics

NRX Pharmaceuticals

Valneva SE

With all eyes on the pandemic once again, these biotech players could be gaining more exposure.

4 Top Biotech Stocks To Watch Now

Investors are looking to capitalize on the latest curveball thrown by the coronavirus contagion.

Why Vir Biotechnology Is Up More Than 13% Today

Apple

American Express

Citigroup

Caterpillar

Celsius Holdings

Dow Inc

Enphase Energy

Gritstone Oncology Inc

Intel

Intrepid Potash

McDonald's

Microsoft

Procter & Gamble

Trillium Therapeutics

Travelers

Walmart

Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 26 weeks out 47 weeks this year in negative conditions above the 40 MG level.

Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

VIR's sotrovimab is a monoclonal antibody that binds to a highly conserved domain on the SARS-COV2 virus. The emergence of the South African variant has shown why mAbs are still highly relevant to treating covid-19 patients.

Vir Biotechnology: mAbs Gaining Traction After New South African Covid Variant

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government

A monoclonal antibody Covid treatment from Vir Biotechnology and GlaxoSmithKline “stands up well” to all variants of the virus, Vir President and CEO George Scangos told CNBC's “Power Lunch” on Wednesday.

CEO of Covid antibody maker Vir Biotech says their treatment 'stands up well' to all variants

Britain's GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GSK to deliver the doses by December 17th   The number of doses of Sotrovimab […] The post U.S. places a sizable order for GSK-Vir's COVID-19 treatment appeared first on Invezz.

U.S. places a sizable order for GSK-Vir's COVID-19 treatment

The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR). GSK said the deal brought the total number of doses secured for the treatment, sotrovimab, to more than 750,000 globally.

US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B

– US government contracts for approximately $1 billion1 (USD) now in place to purchase sotrovimab, further expanding access nationwide –

GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment

The U.S. government has agreed to buy more doses of an antibody drug for the early treatment of Covid-19 developed by GlaxoSmithKline and Vir Biotechnology bringing its total order to nearly $1 billion for a treatment found to reduce the risk of hospitalization.

The Wall Street Journal: U.S. government will buy more of GlaxoSmithKline and Vir's COVID antibody drug

Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.

News for Vir Biotechnology Stock (VIR)